Copyright
©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jul 15, 2023; 15(7): 1262-1270
Published online Jul 15, 2023. doi: 10.4251/wjgo.v15.i7.1262
Published online Jul 15, 2023. doi: 10.4251/wjgo.v15.i7.1262
Efficacy of concurrent chemoradiotherapy with thalidomide and S-1 for esophageal carcinoma and its influence on serum tumor markers
Tian-Wei Zhang, Peng Zhang, Dong Nie, Xin-Yu Che, Tian-Tai Fu, Yan Zhang, Department of Hematology and Radiotherapy, Zibo 148 Hospital, Zibo 255300, Shandong Province, China
Author contributions: Zhang TW and Zhang Y analyzed the data and wrote the manuscript; Zhang TW, Zhang P, Nie D, Che XY and Fu TT designed the research; Zhang TW modified the manuscript; and all authors read and approved the final manuscript.
Institutional review board statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by Medical Ethics Committee of Zibo 148 Hospital.
Informed consent statement: The informed consent was not required as the research was conducted on anonymized data for which consent from the volunteers have already been obtained.
Conflict-of-interest statement: The authors have no conflicts of interest to declare.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan Zhang, MS, Doctor, Department of Hematology and Radiotherapy, Zibo 148 Hospital, No. 20 Zhanbei Road, Zhoucun District, Zibo 255300, Shandong Province, China. zhangyan100862023@163.com
Received: March 28, 2023
Peer-review started: March 28, 2023
First decision: April 10, 2023
Revised: May 2, 2023
Accepted: June 13, 2023
Article in press: June 13, 2023
Published online: July 15, 2023
Processing time: 106 Days and 1.6 Hours
Peer-review started: March 28, 2023
First decision: April 10, 2023
Revised: May 2, 2023
Accepted: June 13, 2023
Article in press: June 13, 2023
Published online: July 15, 2023
Processing time: 106 Days and 1.6 Hours
Core Tip
Core Tip: Esophageal carcinoma (EC) is a common and fatal digestive tract tumor, and the current therapeutic methods such as surgical resection, radiotherapy and chemotherapy have limited effects and are accompanied by relatively serious adverse events. Therefore, clinical exploration of new treatment strategies for esophageal cancer should be continued to optimize the management of EC patients.